Atlas Venture Life Science Advisors, LLC
CIK 0001917529 · CAMBRIDGE, MA · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$881.3M
2026 Q2
Positions
7
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
100.0%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
KYMR
Kymera Therapeutics, Inc.
37.1%
DYN
Dyne Therapeutics, Inc.
17.1%
SION
Sionna Therapeutics, Inc.
15.0%
KLRA
Kailera Therapeutics, Inc.
12.9%
IRON
Disc Medicine, Inc.
12.6%
QTTB
Q32 Bio, Inc.
3.9%
KRRO
Korro Bio, Inc.
1.4%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.